Please ensure Javascript is enabled for purposes of website accessibility

Novartis Subsidiary Agrees to Pay $195 Million Over Price-Fixing Charges

By Mark Prvulovic - Mar 2, 2020 at 7:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company admits it was guilty of fixing prices for a number of different products.

Novartis (NVS -0.65%) subsidiary Sandoz has plead guilty in its ongoing price-fixing case. The U.S. Justice Department, which has been investigating price-fixing schemes within the generic-drug industry, has ordered the company to pay a $195 million fine, the largest seen in an American antitrust case so far..

The pharmaceutical giant's subsidiary was accused of fixing prices for more than $500 million worth of generic drugs between 2013 and 2015. The Justice Department has been looking into the generic-drug sector for years, with Sandoz being the third generic-drug maker charged with an antitrust case so far as a result of the broader investigation.

A gavel resting on a stack of hundred dollar bills on a table.

Image source: Getty Images.

"Sandoz conspired for years with other manufacturers and their executives to raise prices for critical medications, and the Antitrust Division will continue its ongoing investigation to hold both individuals and corporations accountable," commented Makan Delrahim, head of the Justice Department's Antitrust Division.

Further details

Three separate executives with Sandoz have pleaded guilty to federal conspiracy charges involving price-fixing. The most recent involves Hector Armando Kellum, who pleaded guilty earlier in February and faces 10 years in prison alongside a $1 million fine.

Sandoz admitted that over $500 million worth of sales were affected by the price-fixing scheme, which includes products for high blood pressure, cystic fibrosis, and common skin conditions. To put it into perspective, Sandoz accounts for around $10 billion -- or 20% -- of Novartis' annual revenue.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novartis AG Stock Quote
Novartis AG
$83.73 (-0.65%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.